Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-

2 infection

Chansavath Phetsouphanh[1*], David Darley[2*], Daniel B Wilson[3], Annett Howe[1], C. Mee Ling

Munier[1], Sheila K Patel[4], Jennifer A Juno[5], Louise M Burrell[4], Stephen J Kent[5, 6], Gregory J

Dore[1, 2], Anthony D Kelleher[1, 2†], Gail V Matthews[1, 2†]

[1] The Kirby institute, University of New South Wales, NSW 2033, Australia

[2] St Vincent's Hospital, Darlinghurst, NSW 2010, Australia

[3] Department of Mathematics and Statistics, Boston University, MA 02215, United States of

America

[4] Department of Medicine, Austin Health, University of Melbourne, Victoria 3084, Australia

[5] Department of Microbiology and Immunology, Peter Doherty Institute, University of

Melbourne, Victoria 3000, Australia

[6] Melbourne Sexual health centre, Infectious Diseases Department, Alfred health, central

Clinical School, Monash University, Melbourne, Victoria 3004, Australia

*, † These authors contributed equally

Correspondence

Dr Chansavath Phetsouphanh

cphetsouphanh@kirby.unsw.edu.au

Prof. Anthony Kelleher

akelleher@kirby.unsw.edu.au

Prof. Gail Matthews

gmatthews@kirby.unsw.edu.au

Abstract

A proportion of patients surviving acute COVID-19 infection develop post-COVID syndrome (long COVID) encompassing physical and neuropsychiatric symptoms lasting longer than 12 weeks. Here we studied a prospective cohort of individuals with long COVID compared to age/gender matched subjects without long COVID (from the ADAPT study), healthy donors and individuals infected with other non-SARS CoV2 human coronaviruses (the ADAPT-C study). We found highly activated innate immune cells and an absence of subsets of un-activated naïve T and B cells in peripheral blood of long COVID subjects, that did not reconstitute over time. These activated myeloid cells may contribute to the elevated levels of type I (IFN-β) and III interferon (IFN-λ1) that remained persistently high in long COVID subjects at 8 months post-infection. We found positive inter-analyte correlations that consisted of 18 inflammatory cytokines in symptomatic long COVID subjects that was not observed in asymptomatic COVID-19 survivors. A linear classification model was used to exhaustively search through all 20475 combinations of the 29 analytes measured, that had the strongest association with long COVID and found that the best 4 analytes were: IL-6, IFN-γ, MCP-1 (CCL2) and VCAM-1. These four inflammatory biomarkers gave an accuracy of 75.9%, and an F1 score of 0.759, and have also previously been associated with acute severe disease. In contrast, plasma ACE2 levels, while elevated in the serum of people previously infected with SARS-CoV-2 were not further elevated in subjects with long COVID symptoms. This work defines immunological parameters associated with long COVID and suggests future opportunities to prevention and treatment.

Introduction

Coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterised by a wide spectrum of clinical severities in the acute phase, ranging from asymptomatic to severe fatal forms [1,2]. Immunological disturbance during acute illness has been well described and is likely to both play a role in host defence and be involved in the pathogenesis of severe COVID-19 [3]. Immunological abnormalities described in the acute phase include significant immune dysregulation with lymphopaenia and elevations in IL-2, IL-6, TGF-β, IL-10, GM-CSF and TNF [3,4].

A proportion of patients surviving acute COVID-19 develop post-COVID syndrome encompassing various physical and neuropsychiatric symptoms lasting longer than 12 weeks, also known as chronic COVID syndrome (CCS), post-acute sequelae of COVID-19 (PASC) and long-haul COVID (long COVID) [5-8]. Although well described following other viral infections including Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-1)[9-11] and Middle East Respiratory Syndrome Coronavirus (MERS-CoV)[12], these syndromes appear commonly following SARS-CoV-2 infection including following initial mild-moderate illness [13-16]. Persistent symptoms 6 months after hospitalization were observed in 76% of discharged patients in a study by Huang *et al*, with the most frequent symptoms reported being muscle weakness and fatigue [17,18]. Amongst community managed COVID-19 cases, prevalence of persisting symptoms is lower, but remains higher than might be expected given the severity of the initial illness, affecting between 10-30% of individuals at 2-3 months post infection, [19,20] continuing out to at least 8 months after initial illness [21]. The spectrum of post-acute sequelae of COVID-19 (henceforth denoted as long COVID) is broad encompassing as many as 50 plus symptoms although characteristically manifests as severe relapsing fatigue often accompanied by dyspnoea, chest tightness, cough and headache [22]. The underlying pathophysiology of long COVID is poorly understood and there is currently little evidence defining the mechanisms of systemic inflammation following COVID-19 and any immune correlates of ongoing symptoms.

We examined a prospective cohort of individuals followed systematically post confirmed

COVID-19 infection (the ADAPT study) and compared them to healthy donors and individuals

contemporaneously infected with other non-SARS CoV2 human coronaviruses (HCoV, ADAPT-

C) to firstly characterise their immunological features up to 8 months post COVID-19 infection

and secondly to compare those with and without persisting symptoms at this time point.

Serum profiles of 29 analytes from 62 patients, 31 with long COVID and 31 matched

asymptomatic controls were evaluated at 5- and 8-months post SARS-CoV-2 infection.

Immune profiles identified in COVID-19 were compared with subjects who had been infected

with common cold coronaviruses (HCoV-NL63, O229E, OC43 or HKU1) and unexposed healthy

donors.

Methods

Cohort Characteristics

The ADAPT study is a prospective cohort study of post-COVID-19 recovery established in April

2020 [21]. 147 participants with confirmed SARS-CoV-2 infection were enrolled, the majority

following testing in community based clinics run by St Vincent's Hospital Sydney, with some

patients also enrolled with confirmed infection at external sites. Initial study follow-up was

planned for 12 months post-COVID-19, and subsequently extended to 2 years. Extensive

clinical data and a biorepository was systematically collected prospectively. The aims of

ADAPT are to evaluate a number of outcomes after COVID-19 relating to pathophysiology,

immunology and clinical sequalae. Laboratory testing for SARS-CoV-2 was performed using

nucleic acid detection from respiratory specimens with the EasyScreen™ Respiratory

Detection kit (Genetic Signatures, Sydney, Australia), and the EasyScreen™ SARS-CoV-2

Detection kit. Two ADAPT cohort sub-populations were defined based on initial severity of

COVID-19 illness; 1. patients managed in the community and 2. patients admitted to hospital

for acute infection (including those requiring intensive care support for acute respiratory

distress syndrome (ARDS). Patients were defined as 'long COVID' at 4-months based on the

presence of any ≥ 1 of the following; fatigue, dyspnoea or chest pain [21]. These patients were

gender and age (+/- 10 years) matched with ADAPT participants without long COVID (Matched

ADAPT controls) (Table 1). Samples for these analyses were collected at the 3-, 4- and 8-

month assessments. Our cohort of n=62 (31 long COVID and 31 matched controls); enrolment

visits were performed at median 76 (IQR 64-93) days after initial infection. Their 4 month

assessments were performed at median 128 (IQR 115-142) days after initial infection (4.2

months). Their 8 month assessments were performed at median 232 (IQR 226-253) days after

initial infection (7.7 months). 4 participants did not complete the 8-month assessment after

the 4-month assessment. The reasons for this include- did not attend (n=2) and Lost to

Follow-up (n=2). A further population of patients presenting to St Vincent's Hospital clinics

for COVID-19 testing on the multiplex respiratory panel who were PCR positive for any of the

4 human common cold coronaviruses (HCoV-NL63, O229E, OC43 or HKU1) and PCR negative

for SARS-CoV-2 were recruited into the ADAPT-C sub study and used as a comparator group.

Ethics

The ADAPT study was approved by the St Vincent's Hospital Research Ethics Committee

(2020/ETH00964) and is a registered trial (ACTRN12620000554965). ADAPT-C sub study was

approved by the same committee (2020/ETH01429). All data were stored using REDCap

electronic data capture tools. Unexposed healthy donors were recruited through St Vincent's

Hospital and was approved by St Vincent's Hospital Research Ethics Committee

(HREC/13/SVH/145). The University of Melbourne unexposed donors were approved by

Medicine and Dentistry HESC-Study ID 2056689. All participants gave written informed

consent.

Sample processing and Flow cytometry

Blood was collected for biomarker analysis (SST 8.5mLs x 1 (Serum) and EDTA 10mLs x 1

(Plasma)) and 36mLs was collected for PBMCs (ACD 9mLs x4). Phenotyping of PBMC was

performed as described previously [23]. Briefly, cryopreserved PBMCs were thawed using RPMI

(+L-glut) medium (ThermoFisher Scientific, USA) supplemented with Penicillin/Streptomycin

(Sigma-Aldrich, USW), and subsequently stained with antibodies binding to extracellular

markers. Extracellular panel included: Live/Dead dye Near InfraRed, CXCR5 (MU5UBEE), CD38

(HIT2) (ThermoFisher Scientific, USA); CD3 (UCHT1), CD8 (HIL-72021), PD-1 (EH12.1), TIM-3

(TD3), CD27 (L128), CD45RA (HI100), IgD (IA6-2), CD25 (2A3), and CD19 (HIB19) (Biolegend,

USA); CD4 (OKT4), CD127 (A019D5), HLA-DR (L234), GRP56 (191B8), CCR7 (G043H7) and CD57

(QA17A04) (BD Biosciences, USA). Perm Buffer II (BD Pharmingen) was used for intracellular

staining of granzyme B (GB11, BD Biosciences). Samples were acquired on an Cytek Aurora

(Biolegend, USA) using the Spectroflo software. Prior to each run, all samples were fixed in

0.5% Paraformaldehyde.

Serum Analytes

LEGENDplex™ Human Anti-Virus Response Panel (IL-1β, IL-6, IL-8, IL-10, IL-12p70, IFN-α2, IFN-

β, IFN-λ1, IFN-λ2/3, IFN-γ, TNF-α, IP-10, GM-CSF) and custom-made panel (IL-5, IL-9, IL-13, IL-

33, PD-1, sTIM-3, sCD25, CCL2(MCP-1), Pentraxin-3(PTX3), TGF-β1, CXCL9(MIG-1), MPO,

PECAM-1, ICAM-1, VCAM-1) were purchased from Biolegend (San Diego, CA, USA) and assays

performed as per manufacturer's instructions. Beads were acquired and analysed on BD

Fortessa X20 SORP (BD Biosciences, San Jose, CA, USA). Samples were run in duplicate, and

4000 beads were acquired per sample. Data analysis was performed using Qognit

LEGENDplex™ software (Biolegend, San Diego, CA, USA). Lower limit of detection (LOD) was

values were used for all analytes at the lower limit.

Catalytic ACE2 detection in plasma

Plasma ACE2 activity was measured using a validated, sensitive quenched fluorescent

substrate-based assay as previously described [24]. Briefly, plasma (0.25 ml) was diluted into

low-ionic-strength buffer (20 mmol/L Tris-HCl, pH 6.5) and added to 200 *m*l ANXSepharose 4

Fast-Flow resin (Amersham Biosciences, GE Healthcare, Uppsala, Sweden) that removed a

previously characterized endogenous inhibitor of ACE2 activity. After binding and washing,

the resulting eluate was assayed for ACE2 catalytic activity. Duplicate samples were incubated

with the ACE2-specific quenched fluorescent substrate, with or without 100 mM

ethylenediaminetetraacetic acid. The rate of substrate cleavage was determined by

comparison to a standard curve of the free fluorophore, 4-amino-methoxycoumarin (MCA;

Sigma, MO, USA) and expressed as *r*mole of substrate cleaved/mL of plasma/min. The intra-

assay and inter-assay coefficient of variation was 5.6% and 11.8% respectively. Samples

below the limit of detection were designated 0.02 (half the LOD – ie 50% x 0.04).

Linear Model

The four analytes most associated with long COVID were identified via Linear Classification.

For an arbitrary set of four analytes, let the concentration of the ith analyte after four and

eight months be denoted a_i^{4M} and a_i^{8M}, respectively. Linear Classification assigns two weights

w_i^{4M} and w_i^{8M} to each analyte. A linear function of these concentrations and weights takes

the form $(\vec{a})$ is a threshold parameter. The weights w_i^{4M} and w_i^{8M} as well as the threshold

parameter θ are selected to maximise the predictive power of the linear classifier by training

on the analyte data.

200
$$f(\vec{a}) = w_\theta + \sum_{i=1}^{N} w_i{}^{4M} a_i{}^{4M} + \sum_{i=1}^{N} w_i{}^{8M} a_i{}^{8M}$$

The data are standardized prior to training, each analyte was rescaled to have zero mean and

unit variance across all participants, thus removing the possibility of a single analyte

dominating the classifier. Then for a given set of four analytes we stratified our data into a

training set and a testing set. Due to the moderately small sample size of 58 participants we

choose our training set to include all but one participant. The excluded participant does not

influence the training of the classifier and is used to test the accuracy of the classifier. There

are four possible outcomes; true positive (TP: both the classifier and data say the participant

had long COVID), true negative (TN: both the classifier and data say the participant had

asymptomatic COVID), false positive (FP: classifier predicts the participant will have long

COVID but the data disagrees) and false negative (FN: classifier predicts the participant will

have asymptomatic COVID but the data disagrees). Each participant is removed in turn to be

the test data, and thus a total of 58 classifiers were trained and the number of TPs, TNs, FPs

and FNs were recorded. This step is known as cross validation and removes the possibility of

bias in the way the training and test data is selected. Thus for a given set of four analytes we

measure how well they predict long COVID with two metrics.

Firstly, the accuracy is defined as TP+TN/n and measures the proportion of test participants

that had their COVID status correctly predicted. The second measure is the F1 score and is

defined as $TP/(TP + 0.5 \times (FP + FN))$, which is a measure that combines recall, how many

long COVID cases were correctly predicted, and precision, of all the participants predicted to

have long COVID how many were correct. The accuracy and F1 score are used to select which

combination of four analytes are most associated with long COVID. For four analytes there

are a total of 20475 combinations. The best four analytes are selected by identifying the four

analytes that achieve the highest accuracy. If two or more sets of four analytes have the

highest accuracy we defer to the F1 score to identify the best set of four analytes. The training

of the many classifiers was performed in Python3 using the Scikit-learn machine learning

package.

Dimensional Reduction and Clustering Analysis

FCS3.0 files were compensated manually using acquisition-defined matrix as a guide, and

gating strategy was based on unstained or endogenous controls. Live singlets were gated from

long COVID and asymptomatic matched controls using Flowjo v.10.7.2, samples were

decoded and statistical analysis between groups and unsupervised analysis was performed,

with matched asymptomatic controls as the primary comparator group. For unsupervised

analysis, the following FlowJo plugins were used: DownSample (v.3), TriMap (v.0.2),

Phenograph (v.3.0) and ClusterExplorer (v.1.5.9) (all FlowJo LLC). First, 100 000 events per

sample were downsampled from the total live singlet gate (Supp. Fig. 1). The newly generated

FCS files were labelled according to control or patient group (long COVID or matched controls)

and concatenated per group. Subsequently, 20, 000 events were taken from each grouped

sample by downsampling. The two new FCS files corresponding to long COVID and matched

controls were then concatenated for dimensionality reduction analysis using TriMap (40, 000

events in total). TriMap was conducted using the following parameters- to include the

markers CD25, CD38, CCR7, CD19, IgD, CD45RA, PD-1, TIM-3, CD4, CD57, CD127, CD27, HLA-

DR, CD8, CXCR5,GPR56 and Granzyme B, and using the following conditions: metric =

euclidean, nearest neighbours = 15, and minimum distance = 0.5. Phenograph plugin was then

used to determine clusters of phenotypically related cells. The same markers as TriMap and

parameters k = 152 and Run ID = auto was used for analysis. Finally, ClusterExplorer plugin

was used to identify the phenotype of the clusters generated by phenograph.

Statistical Analysis

All column graphs are presented as medians with inter-quartile ranges. One-way ANOVA

utilising Kruskal-Wallis and Dunn's correction for multiple comparisons was used for serum

analyte analysis. Wilcoxon paired *t* test was used to analyse statistical data employing Prism

9.0 (GraphicPad, La Jolla, CA, USA) software. For unpaired samples Mann-Whitney U test was

used. RStudio version 1.2.1335 was used to generate correlograms utilizing corrplot package

with Spearman's method used to determine Rho values and cor.mtest with 95% confidence

level was used to determined *p* values. *p* values <0.05 were considered significant (*<0.05,

<0.01, *<0.001, and ****<0.0001).

Results

The ADAPT cohort

All participants were drawn from a single prospective observational cohort designed to follow

patients after acute COVID-19 infection. The ADAPT study[16] enrolled all adults with SARS-CoV-

2 infections confirmed by polymerase chain reaction (PCR) at St Vincent's Hospital community

based testing clinics in Sydney (Australia), who were able to be contacted and agreed to

participate (70.5% of those diagnosed). Participants were prospectively systematically

assessed according to a pre-defined schedule which included routine visits at enrolment,

month 4 and month 8. The study was commenced as soon as ethics approval was obtained

and for the majority of participants in the first wave, the first enrolment visit occurred

somewhere between month 2-3 post infection (median 79 days)[16,21] with 93.6% and 84.5% of

participants completing subsequent month 4 (median 128 days) and month 8 (median 232

days) visits timed from the date of diagnosis of their initial infection (Table 1). The drop-out

rate has been very low to date: approximately 9.4% at 12 months. Participants were

designated as Long COVID (LC) based on the presence of one of three major symptoms

(fatigue, dyspnoea or chest pain) at the month 4 timepoint. These participants were age and

gender matched with 31 participants from the same cohort who reported no ongoing

symptoms at the 4 month timepoint (designated as matched controls (MC)) (Suppl. Table 1).

The matched control group were symptomatic at acute initial infection (Suppl. Table 2), but
did not develop long COVID and were asymptomatic at month 4. In terms of clinical recovery,
there was a 10% trend towards some improvement over time, but this was not statistically
significant, Fischer Exact p=0.44. With regard to the external enrolments (29.5%), we also
allowed enrolment in the study for some participants who were diagnosed outside of the St
Vincent's testing clinic. In these cases participants were required to have documented
evidence of a positive swab and entered into the same schedule of assessments for follow-
up.
289
290 *Elevated levels of pro-inflammatory cytokines following SARS-CoV-2 infection that are*
291 *maintained at 8 months*
292
In order to assess biomarkers associated with recovery from symptomatic SARS-CoV-2
infection 28 analytes were analysed from serum of convalescent subjects with long COVID
(LC) or asymptomatic matched controls (MC) at 4 months post-infection. Individuals that were
PCR positive for prevalent common cold coronaviruses (HCoV) and sampled within the same
time frame following infection (3-6months) and unexposed healthy donors sampled prior to
December 2019, were used as comparator groups. Six pro-inflammatory cytokines were
highly elevated in the two COVID-19 convalescent ADAPT groups compared to control groups
(Fig. 1A), while no difference was observed with the 22 other analytes (Supp. Fig. 2A&B). It is
noteworthy that no difference was observed between long COVID and asymptomatic
matched controls for any of the individual analytes examined at 4 months post infection. Type
I interferon-β (IFN-β) was 7.92-fold (median values shown in Supp. Fig 2C) and 7.39-fold
higher in LC and MC compared to HCoV (both *p<0.0001*), and 7.32- and 6.83-fold higher
compared to unexposed healthy controls (both *p<0.0001*, respectively). Type III interferon-
lamdba1 (IFN-λ1) was 2.44-fold and 3.24-fold higher in LC and MC compared to HCoV (both
p<0.0001), and 2.42- and 3.21-fold higher compared to unexposed, (*p<0.01 and p<0.001*,
respectively). This was also the case for IL-8 (CXCL8) levels; LC (3.43-fold) and MC (3.56-fold)
higher compared to both HCoV and unexposed (all *p<0.0001*). Interferon gamma induced
chemokine CXCL10 (IP-10) was elevated in LC and compared to HCoV 2.15-fold (*p<0.001*) and
unexposed 3.20-fold (*p<0.001*), similarly MC group were also significantly higher than
comparator groups (1.7-fold, *p<0.05* and 3.06-fold, *p<0.01,* respectively). CXCL9(MIG-1) was

1.69-fold higher than unexposed (*p<0.*05), and soluble TIM-3 levels were only elevated in LC

and not MC when compared to HCoV comparator group 1.46-fold (*p<0.05*).

To elucidate the persistence of these elevated analytes over a longer period of time, serum

from all available subjects at 8 months were examined and compared with levels at 4 months

(Fig. 1B). Decreases of both IFN-β and IFN-λ1 in MC group at 8 months were observed 4.4-

fold (9.36[6.25-21.35] pg/mL, *p<0.0001*) and 1.8-fold (10.51[7.72-16.30] pg/mL, *p<0.05*)

respectively. However this was not the case for LC group, where IFN-β slightly decreased by

1.5-fold (22.32[18.75-49.07] pg/mL) and IFN-λ1 slightly increased by 1.05-fold (16.87[9.60-

24.09] pg/mL) at 8 months, albeit not statistically significant. Overall, type I and type III

interferons remained high in LC subjects and was significantly higher than the MC group at 8

months post-infection (*p<0.05*, for both interferons) and was higher than HCoV and

unexposed groups (Suppl. Fig. 3A). Reduction of CXCL9 (MIG-1), CXCL10 (IP-10), IL-8 and sTIM-

3 were evident in both groups at 8 months. There were also decreases in the levels of some

of the 22 analytes not significantly different to control groups at month 4 by month 8 (Supp.

Fig. 3B&C).

Elevated levels of ACE2 in SARS-CoV-2 convalescent subjects

Plasma ACE2 activity levels have recently been shown to be elevated out to a median of 114

days following SARS-CoV-2 infection[25], and we sought to investigate whether this was the

case within the ADAPT longitudinal cohort at 3-, 4- and 8-months post-infection. At 3-months

post-infection, median plasma ACE2 activity was significantly higher in both LC and MC groups

compared to HCoV (LC=1.92 [0.02-7.36], MC=2.47 [0.63-5.94] *versus* HCoV =0.02 [0.02-1.99]

pmol/min/mL, *p<0.01* and *p<0.001* respectively). These levels remained elevated at 4 months

post-infection in both groups (LC=1.75 [0.02-5.01], MC=2.62 [0.36-6.3] *versus* HCoV =0.02

[0.02-1.99] pmol/min/mL, *p<0.05* and *p<0.001* respectively). Plasma ACE2 activity decreased

at 8 months for LC (0.02[0.02-1.36] pmol/min/mL) and MC (0.18[0.02-3.46] pmol/min/mL).

No significant difference was observed between these groups at 3, 4 and 8-months or when

compared to HCoV. It appears that increased plasma ACE2 activity is specific to SARS-CoV-2

infection and is not a common feature of other coronaviruses.

High inter-analyte correlations in long COVIDs at 4 months

Immune responses to viral infections involve communication of multiple specialised cell

populations through direct interactions, secreted cytokines and various mediators in a

concerted effort to combat the infectious agent. To obtain a broader scope of systems-level

interactions during convalescence, we generated correlation matrices from 29 analytes

measured at 4 months post-infection (Fig. 3). This analysis revealed multiple positive

correlations across a spectrum of 18 markers   including: IFN-α2, IFN-λ1, IFN-λ2/3

(interferons), IL-1β, IL-33 (IL-1 family cytokines); IL-12p70, MCP-1 (CCL2), IL-6, TGF-β1, CXCL-

9 (myeloid activation), PD-1, sCD25 (T cell activation,) IFN-γ, TNF-α (Type 1 (Th1) cytokines);

IL-5, IL-9, IL-13, (Type 2 (Th2) cytokines) and GM-CS in the LC group most of which were not

present in the asymptomatic MC group. (Fig. 3 A&B). However at 8 months this profile had

altered in both groups (Supp. Fig. 4A&B). This profile was not observed in HCoV (Supp. Fig.

4C) or unexposed donors (Supp. Fig. 4D).

Linear modelling defines 4 features most highly associated with long COVID

To identify a subset of the 29 analytes that are most strongly associated with long COVID we

use linear classification. We trained our linear classifiers with data from 58 participants (29

with long COVID and 29 matched controls) with analyte concentrations after 4 and 8 months.

The optimal number of analytes giving the highest accuracy when using a linear classifier to

predict whether a participant suffered from long or asymptomatic COVID was 4. By

exhaustively searching through all 20475 combinations of 4 analytes we found that the 4

analytes IL-6, IFN-γ, MCP-1 (CCL2) and VCAM-1 gave an accuracy of 75.9%, and an F1 score

of 0.76 (Fig. 3C). Beyond identifying the four analytes that are most highly associated with

long COVID, linear classifiers offer a simple test to predict whether or not a patient will suffer

from long COVID. Linear classifiers define what is known as a decision boundary. A patient's

4 analyte concentrations at 4 and 8 months will lie on either side of this boundary, and which

side it is will determine whether or not the patient is predicted to experience long or

asymptomatic COVID. The decision boundary for the 4 best analytes is eight-dimensional due

to both the 4- and 8-month data. However, we can visualise the domain boundary with two-

dimensional projections of IFN-γ, against MCP-1, MCP-1 against VCAM-1 and VCAM-1 against

IL-6 as shown in Fig, 3D.

Highly activated innate cells combined with absence of un-activated naïve T and B cell subsets-

a distinguishing feature of long COVID

To investigate differences in immune cell phenotypes between LC and MC, a 19-parameter

phenotyping panel was developed and utilised for PBMC samples from LC and MC groups at

3 months and 8 months following infection, with MC group being the primary comparator.

Dimensional reduction via TriMap coupled with Phenograph clustering identified 24 distinct

cell clusters at month 3 and 21 clusters at month 8 (example of cell cluster identification

shown in Suppl. Fig. 5A); comprising T cells, B cells, NK cells and non-lymphoid (myeloid) cells

(Supp. Fig. 5B&C). Of the 24 subsets identified at month 3, five were absent in LC subjects

(Fig. 4A), these include:- 1) CD127^{low}GzmB-CCR7+CD45RA+CD27+ naïve CD8+ T cells, 2) CD57+

highly cytotoxic (GPR56+GzmB+) CD8+ T cells, 3) CD127^{low}TIM-3^{neg}CCR7+CD45RA+CD27+

naïve CD4+ T cells, 4) CD3+CD4-CD8- innate like T cells (may comprise NKT cells and γδ-T cells),

and 5) naïve CD38^{low}CD27-IgD+ B cells. At 8 months only 3 populations remined absent: 1)

CD127^{low}GzmB-CCR7+CD45RA+CD27+   Naïve   CD8+   T   cells,   2)   CD127^{low}TIM-

3^{neg}CCR7+CD45RA+CD27+ Naïve CD4+ T cells, and 3) CD38^{low}CD27-Naïve IgD+ B cells (Fig. 4B).

These findings are indicative of ongoing inflammation through to 8 months in LC subjects.

There was no reconstitution of these un-activated naïve T and B cell subsets even at 8 months

post-infection in peripheral blood, however other naïve subsets that appear more activated

are present in LC. All concatenated patients sampled (7 LC, 7 MC and 7 unexposed)

contributed to all populations identified (Suppl. Fig 6A-D). These un-activated T and B cells

are evident in unexposed and MC comparator groups.

Highly activated non-lymphoid cells (defined by the co-expression of CD38+HLA-DR+)

remained elevated at 8 months in LC (Fig. 4C). In contrast, activation markers on non-

lymphoid cells decreased over time in asymptomatic matched controls (median 3 months=

11.2[3.43-12.5] and 8 months= 8.12[2.07-9.23], *p<0.05*). Activate monocytes (CD14+CD16+)

were higher in LC compared to MC at both 4 and 8 months (3.74-fold, *p<0.05*, and 4-fold,

p<0.01, respectively) (Fig. 4D). Plasmacytoid dendritic cells expressing activated markers

CD86+ CD38+ were also higher in LC at both timepoints (2.14-fold, *p<0.01* and 4.88-fold,

p<0.001, respectively) (Fig. 4E). No differences in activation of myeloid dendritic cells were

observed (Suppl. Fig. 7A). Notably, the immune checkpoint receptor commonly associated

with T cell activation/exhaustion PD-1 was highly expressed on CD8+ T cells at 3 and 8 months

in LC compared to MC (3.04-fold, *p<0.001* and 2.86-fold, *p<0.0001*)(Fig. 4F). T cell exhaustion

marker Tim-3 was also higher in LC at month 3 (1.6-fold, *p<0.05*), but decreased at month 8

(Fig. 4G). However, no difference was observed between LC and MC as judged by co-

expression of PD-1 and Tim-3 on CD4+ and CD8+ T cells (suppl. Fig. 7B).

Discussion

Our study demonstrates several unique and important findings in relation to understanding

long-term outcomes from COVID-19. We show that convalescent profiles post COVID-19 are

different from other coronaviruses. Several cytokines, mostly type I and III interferons, but

also chemokines down stream of IFN-γ, were highly elevated in people following resolution

of active SARS-CoV-2 infection compared to HCoV and unexposed controls at 4 months. IFN-

β and IFN-λ1 remained high in long COVID to 8 months after initial infection, while the levels

of these two cytokines had begun to resolve in the matched controls. This finding was

observed irrespective of persistent long COVID symptoms. We also demonstrated an

elevation of plasma ACE2 levels at 4 months post COVID infection with the degree of

elevation not being different between those with and without long COVID symptoms. ACE-2

levels trended towards normal by 8 months. Further, by employing a linear classification

model we identified 4 biomarkers highly associated with long COVID: IL-6, IFN-γ, MCP-1 (CCL2)

and VCAM-1. This indicates that components of the acute inflammatory response, T cell,

Myeloid cell and vascular endothelium activation are associated with long COVID.

Interestingly, immune cell phenotyping revealed chronic activation of: a subset of CD8 T cells

with expansion of PD-1 and Tim-3 positive subsets; plasmacytoid dendritic cells; and

monocytes (CD38 and HLA-DR co-expression) in long COVID patients. Levels of these subsets

are increased in long COVID patients relative to matched controls at 3 months with

perturbations persisting out to 8 months.   Further, there is an apparent turnover of un-

activated naïve T and B cell subsets in peripheral blood in long COVID subjects over the same

time period. This suggests maintenance of long-lasting inflammation and immune activation

in these individuals. Together these findings suggest that SARS-CoV-2 infection exerts a

unique residual prolonged effect on aspects of both the innate and adaptive immune systems,

and that this may be driving the post COVID symptomology known as 'long COVID'.

Type I and III Interferons, namely IFN-β and IFN-λ1 were highly elevated in our COVID-19

convalescent subjects compared to HCOV and unexposed subjects,. While their levels

decreased over time in recovered subjects they remained high in those with long COVID. IFN-

β can be expressed by most cell types and can be induced early during viral infection, before

most IFN-α subtypes [26-28].   IFN-λ1 or IL-29 can also be induced in a broad range of cell types

including epithelial cells by stimulation of toll-like receptors (TLRs), Ku70, and RIG-1-like

receptor [29], however, as for type I interferons, the main producers were found to be type 2

myeloid dendritic cells (plasmacytoid DCs)[30-32]. Type I interferon receptors are widely

expressed on immune cells, and IFN-β responses during influenza and SARS-CoV-1 infection

can result in immunopathology [33,34]. In contrast, IFN-λ receptors are mainly expressed at

epithelial barriers and confer localised antiviral protection [35,36]. The morbidity of acute COVID-

19 infection appears to correlate with high expression of type I and III interferons in the lung

of patients [37]. Furthermore IFN-λ produced by dendritic cells in lungs of mice in response to

synthetic viral RNA is associated with damage to lung epithelium [38], and IFN-λ signalling can

hamper lung repair during influenza infection of mice [39]. Diminished type I interferon and

enhanced IL-6 and TNF-α responses in severe acute COVID-19 patients were reported by

Hadjadj *et al* [38]. Our cohort of long COVID subjects, however, mostly consisted of patients

with mild and moderate initial illness, and maintenance of elevated type I and III interferon

levels at 8 months demonstrates ongoing inflammation within these individuals and is

consistent with our observation of prolonged activation of plasmacytoid dendritic cells.

CXCL9 (MIG-1) and CXCL10 (IP-10) are pro-inflammatory T cell chemo-attractants that are

expressed by monocytes, endothelial cells, and fibroblasts downstream of interferon-gamma

signalling [40]. Upon engagement with their receptor CXCR3, mainly expressed on T cells, they

drive naïve CD4+ T cell differentiation into effector Th1 cells, as well as recruiting CD4+ and

CD8+ T cells in sites of tissue damage, which has been documented during vascular disease

and pulmonary fibrosis [41,42]. Both chemokines have been implicated in symptomatic acute

coronavirus infections, including COVID-19, where levels were higher in severe compared to

asymptomatic subjects [43]. Similarly, CXCL8 (IL-8) produced by lung epithelium and airway

resident macrophages, has previously been shown to be released by lung cells after activation

by spike proteins from SARS-CoV-1 [44]. CXCL8 acts as a chemoattractant that facilitates

migration of inflammatory T cells and neutrophils, that may contribute to alveolar damage

[45,46]. Further the elevation of CXCL9 (MIG-1) and CXCL10 (IP-10) is consistent with persistent

absence of un-activated naïve cell subsets in peripheral blood that we observed in the long

COVID group.

Increased shedding or cleavage of ectodomains of cell surface proteins during inflammation

has been well documented [47,48]. Increased levels of soluble T-cell immunoglobulin mucin

domain-3 (sTIM-3) a marker of T-cell activation and exhaustion has been reported in chronic

viral infections (i.e., HIV, hepatitis B and C)[49-51] where there is persistent antigenic stimulation,

and recently in COVID-19 infection, where patients admitted to ICU had high plasma levels of

sTIM-3 and myeloperoxidase (MPO) [52]. Elevated sTIM-3 levels were seen in those with long

COVID, but not recovered subjects or those with other HCoV, and is entirely consistent with

our observation of expanded subsets of memory CD8 T cells expressing Tim-3 and PD-1 in the

same group who appear to have chronic T cell activation and potentially T cell exhaustion

perhaps partially driven by the prolonged presence of activated antigen presenting cells and

the downstream drivers of T cell activation such as type I interferons and the IFN-γ driven

chemokines CXCL9 and CXCL10 . Another membrane bound protein found to be 'shed' during

COVID-19 is ACE2, which is also an important receptor for viral host cell entry [53]. Patel *et al*

showed that shedding of ACE2 from the cell membrane resulted in increased plasma ACE2

activity levels in convalescent COVID-19 subjects [25]. Our data corroborates with this finding,

where elevated plasma ACE2 activity occurred in COVID-19 infection regardless of symptom

severity, at a higher level than HCoV and unexposed, persisted at 4 months, and decreased at

8 months in most subjects.

We observed high inter-analyte correlations in long COVIDs at 4 months that was not

observed in MC, HCoV or unexposed comparator groups. These correlations reinforced the

idea that there was interrelated activation of acute phase inflammatory , innate and adaptive

immune responses. This profile was less prominent at 8 months. In order to assess across all

combinations of analytes those most strongly associated with long COVID, a linear classification model was employed. A combination of 4 biomarkers, IL-6, IFNγ, MCP-1 (CCL2), and VCAM-1 was identified as being the most accurate correlate of long COVID. These analytes could be more prominent at the acute stage of infection. IL-6 is a pleiotropic mediator that has an effect on inflammation and immune activation [54]. IFNγ produce by NK and T cells have anti-viral activity and levels are associate with a heightened inflammatory state. High IL-6/IFN-gamma ratio was found to be associated with severe disease in COVID-19 patients at acute infection [55]. MCP-1 (CCL2) is a chemokine that is produced by many cell types (endothelial, fibroblasts, epithelial, monocytic etc [56]) and acts as a chemoattractant for monocyte, NK, neutrophils, basophils, B and T cells and is involved in T cell activation [57]. VCAM-1 mediates adhesion of immune cells to the endothelium and has been implicated in inflammatory processes ranging from atherosclerosis and rheumatoid arthritis [58]. Recent meta-analysis of > 300,000 single-cell transcriptomic profiles from COVID-19-affected lungs have found that IFNγ together with TNFα drive an drive a IP-10+CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation [59]. These analytes could be more prominent at the acute stage of infection and warrants further investigation. The observation that the best correlate of the presence of long COVID is an eclectic combination of biomarkers reinforces breadth of host response pathways that are activated during long COVID.

Finally, T cell activation via surrogate markers CD38 and HLA-DR, T cell exhaustion, together with an increase in B cell plasmablasts during severe COVID-19 has been reported [60-62]. We found no difference between activation levels as judged by cell surface expression of these molecules on T cells between long COVID and asymptomatic (data not shown) but identified highly activated myeloid cells comprising monocytes and dendritic cells. Elevated levels of CD38+HLA-DR+ myeloid cells decreased over time within asymptomatic subjects but remained unchanged in those with long COVID. It is known that type I and type III interferons upregulate MHC-class expression including HLA-DR [63]. When an unbiased large-scale dimensional reduction using triplets (TriMap) approach was used, we identified 5 population clusters that were absent in those with long COVID. These consisted of mostly un-activated naïve T and B cell subsets (CD4 (CD127^{low}TIM-3^{neg}CCR7+CD45RA+CD27+), CD8 (CD127^{low}GzmB-CCR7+CD45RA+CD27+) and CD127^{low}TIM-3^{neg}CD38^{low}CD27-IgD+ B cells), as

well as double negative (CD4-CD8-) Innate-like T cells and highly cytotoxic
CD57+GPR56+GzmB+ CD8+ T cells at 3 months. The depletion of these un-activated naïve
subsets persisted at the 8-month time-point. Other more activated naïve subsets were
present at 3 months in both groups and remained at 8 months. Naïve T and B cell expressed
low to mid-levels of CD127 in MC and unexposed (Suppl. Fig. 6E&F), but $CD127^{low}Tim-3^{neg}$
phenotype was absent in LC.   Taken together these observations suggest persistent
recruitment of activated naïve T cells, potentially due to by-stander activation secondary to
underlying inflammation and/or antigen presentation by activated plasmacytoid dendritic
cells or monocytes, pushing naïve cells into an activated state, thereby depleting the un-
activated naïve T and B cell pools in those with long COVID. The ultimate result of this chronic
stimulation may be the observed expansion of exhausted PD-1 or Tim-3 positive CD8+ T cells.
Bystander activation of un-activated naïve subsets into more activated phenotypes is
consistent with observations in subsets of patients during acute severe COVID-19 infection
[64,65].

Our data does have some limitations. Firstly, although our long COVID 'cases' and controls
were matched for two major characteristics (age and gender) it is possible that the differences
observed reflect other key demographic or other factors between the groups. While long
COVID group had a higher representation of those with severe acute disease (8 LC and 2 MC),
sensitivity analyses excluding these patients did not substantially alter the statistical
significance any of our major associations. Also, due to timing of ethics approval and trial
setup we were not able to collect samples at acute infection. We are therefore unable to
differentiate whether the elevations in biomarkers seen during convalescence correlate with
levels during the acute infection. A review of the literature of biomarkers during acute
infection suggests that while some of the alterations observed here are potentially consistent
with a hypothesis that the major drivers of the levels of biomarkers in convalescence are
those in the acute infection, others are not. For instance diminished type I interferon and
enhanced IL-6 and TNF-α responses in severe acute COVID-19 patients have been reported
by Hadjadj et al [38]. Our cohort consisted mostly of patients with mild and moderate initial
illness and among our cohort those with long COVID do not have elevated levels of IL6 or TNF,
but do have elevated levels of both type I and III interferon. Although 7 of the 29 serum
analytes were abnormally elevated, key cytokines implicated in other fatigue syndromes, such

as Pentraxin-3(PTX3), TGF-β1, and IL-13[66,67], were not. This suggests long COVID may be
differentiated from other post viral fatigue syndromes, however, our results require
validation in other cohorts of long COVID to ensure their replicability. Finally, our definition
of 'long COVID' cases was internally set given the lack of international consensus regarding
this and thus is not definitive. Nevertheless, the inclusion of three of the commonest
persisting symptoms and the blinding of cases and controls from the laboratory scientists
helps to ensure the validity of our findings. Additional strengths of our study include the
prospective protocol defined collection of samples and data and the establishment of an
ADAPT–C cohort of individuals affected contemporaneously with other human coronaviruses
to act as comparators.

In summary, our data strongly suggest there is an ongoing, sustained inflammatory response
following even apparently mild to moderate acute COVID-19 infection, which is not found
following infections with other prevalent coronaviruses. This process may be asymptomatic
and therefore subclinical and takes more than 8 months to resolve. In those with persistent
long COVID symptoms as distinct from asymptomatic convalescence, there is a sustained
increase, out to at least 8 months, in highly activated myeloid cells, particularly monocytes
and plasmacytoid dendritic cells, that likely contribute to the sustained elevation of
inflammatory cytokines (particularly type I and III interferons), despite the majority of cohort
suffering initial mild-moderate illness. Further, there was evidence of sustained activation of
the adaptive immune system manifesting in perturbations of both naïve and
memory/effector cell compartments with absence of the un-activated naïve T and B cells and
increases in the expression of checkpoint molecules PD-1 and Tim-3 on CD8+ memory T cells.
This widespread activation signature is also reflected in the identification of serum levels of
IL-6, IFN-γ, MCP-1 (CCL2), and VCAM-1 as the 4 features that most strongly associated with
long COVID. The drivers of this activation require further investigation but possibilities include
persistence of antigen, an autoimmune phenomenon driven by unexpected antigenic cross
reactivity, or a reflection of damage repair. To our knowledge, this is the first demonstration
of an abnormal immune profile in COVID-19 patients at extended time points post infection
and provides clear support for the existence of a syndrome of 'long COVID'. While our findings
require validation in other similar cohorts, they provide an important foundation to

understanding further the pathophysiology of this syndrome and potential therapeutic
avenues for intervention.
600

Acknowledgements

The authors thank the staff at the St Vincent's Institute for Applied Medical Research-Clinical
Trials Unit for their expertise in specimen processing and bio-banking. We appreciate grant
support from the St Vincent's Clinic Foundation, the Curran Foundation, the Rapid Response
Research Fund (UNSW) and the Medical Research Futures Fund (Australia). SKP and LMB-
NHMRC programme grant APP 1055214 (LMB), Medical Research Future Fund award GNT
1175865, Austin Medical Research Foundation Grant. DBW- NSF-DMA grant 1902854, SJK and
JAJ- the Victorian Government, MRFF Award (2005544), NHMRC program grant (1149990
(SJK, ADK), NHMRC Fellowships (1136322-SJK, 1123673-JAJ).

References

1.   Sudre, C.H.*, et al.* Attributes and predictors of long COVID. *Nat Med* **27**, 626-631
(2021).
2.   Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J. & Prescott, H.C.
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease
2019 (COVID-19): A Review. *JAMA* **324**, 782-793 (2020).
3.   Carvalho, T., Krammer, F. & Iwasaki, A. The first 12 months of COVID-19: a timeline of
immunological insights. *Nat Rev Immunol* **21**, 245-256 (2021).
4.   Zhu, N.*, et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N
Engl J Med* **382**, 727-733 (2020).
5.   Baig, A.M. Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-
2 on the CNS in Chronic COVID Syndrome. *ACS Chem Neurosci* **11**, 4017-4020 (2020).
6.   Baig, A.M. Chronic COVID syndrome: Need for an appropriate medical terminology for
long-COVID and COVID long-haulers. *J Med Virol* **93**, 2555-2556 (2021).
7.   Peluso, M.J.*, et al.* Rapid implementation of a cohort for the study of post-acute
sequelae of SARS-CoV-2 infection/COVID-19. *medRxiv* (2021).
8.   Sykes, D.L.*, et al.* Post-COVID-19 Symptom Burden: What is Long-COVID and How
Should We Manage It? *Lung* **199**, 113-119 (2021).
9.   Hui, D.S.*, et al.* Impact of severe acute respiratory syndrome (SARS) on pulmonary
function, functional capacity and quality of life in a cohort of survivors. *Thorax* **60**, 401-
409 (2005).
10.   Hui, D.S. An overview on severe acute respiratory syndrome (SARS). *Monaldi Arch
Chest Dis* **63**, 149-157 (2005).

11.   Lam, M.H., *et al.* Mental morbidities and chronic fatigue in severe acute respiratory
638   syndrome survivors: long-term follow-up. *Arch Intern Med* **169**, 2142-2147 (2009).
639   12.   Ahmed, H., *et al.* Long-term clinical outcomes in survivors of severe acute respiratory
640   syndrome and Middle East respiratory syndrome coronavirus outbreaks after
641   hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil*
642   *Med* **52**, jrm00063 (2020).
643   13.   Townsend, L., *et al.* Persistent fatigue following SARS-CoV-2 infection is common and
644   independent of severity of initial infection. *PLoS One* **15**, e0240784 (2020).
645   14.   Halpin, S.J., *et al.* Postdischarge symptoms and rehabilitation needs in survivors of
646   COVID-19 infection: A cross-sectional evaluation. *J Med Virol* **93**, 1013-1022 (2021).
647   15.   Carfi, A., Bernabei, R., Landi, F. & Gemelli Against, C.-P.-A.C.S.G. Persistent Symptoms
648   in Patients After Acute COVID-19. *JAMA* **324**, 603-605 (2020).
649   16.   Darley, D.R., *et al.* Persistent symptoms up to four months after community and
650   hospital-managed SARS-CoV-2 infection. *Med J Aust* **214**, 279-280 (2021).
651   17.   Cortinovis, M., Perico, N. & Remuzzi, G. Long-term follow-up of recovered patients
652   with COVID-19. *Lancet* **397**, 173-175 (2021).
653   18.   Huang, C., *et al.* 6-month consequences of COVID-19 in patients discharged from
654   hospital: a cohort study. *Lancet* **397**, 220-232 (2021).
655   19.   Sudre, C.H., *et al.* Anosmia and other SARS-CoV-2 positive test-associated symptoms,
656   across three national, digital surveillance platforms as the COVID-19 pandemic and
657   response unfolded: an observation study. *medRxiv* (2020).
658   20.   Tenforde, M.W., *et al.* Characteristics of Adult Outpatients and Inpatients with COVID-
659   19 - 11 Academic Medical Centers, United States, March-May 2020. *MMWR Morb*
660   *Mortal Wkly Rep* **69**, 841-846 (2020).
661   21.   Darley, D., *et al.* Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at
662   eight months in a prospective cohort. *medRxiv*, 2021.2003.2029.21254211 (2021).
663   22.   Lopez-Leon, S., *et al.* More Than 50 Long-Term Effects of COVID-19: A Systematic
664   Review and Meta-Analysis. *Res Sq* (2021).
665   23.   Phetsouphanh, C., *et al.* Maintenance of Functional CD57+ Cytolytic CD4+ T Cells in
666   HIV+ Elite Controllers. *Front Immunol* **10**, 1844 (2019).
667   24.   Lew, R.A., *et al.* Angiotensin-converting enzyme 2 catalytic activity in human plasma is
668   masked by an endogenous inhibitor. *Exp Physiol* **93**, 685-693 (2008).
669   25.   Patel, S.K., *et al.* Plasma ACE2 activity is persistently elevated following SARS-CoV-2
670   infection: implications for COVID-19 pathogenesis and consequences. *Eur Respir J*
671   (2021).
672   26.   Juang, Y.T., *et al.* Primary activation of interferon A and interferon B gene transcription
673   by interferon regulatory factor 3. *Proc Natl Acad Sci U S A* **95**, 9837-9842 (1998).
674   27.   Katze, M.G. Regulation of the interferon-induced PKR: can viruses cope? *Trends*
675   *Microbiol* **3**, 75-78 (1995).
676   28.   Katze, M.G., He, Y. & Gale, M., Jr. Viruses and interferon: a fight for supremacy. *Nat*
677   *Rev Immunol* **2**, 675-687 (2002).
678   29.   Egli, A., Santer, D.M., O'Shea, D., Tyrrell, D.L. & Houghton, M. The impact of the
679   interferon-lambda family on the innate and adaptive immune response to viral
680   infections. *Emerg Microbes Infect* **3**, e51 (2014).
681   30.   Zhang, S., Kodys, K., Li, K. & Szabo, G. Human type 2 myeloid dendritic cells produce
682   interferon-lambda and amplify interferon-alpha in response to hepatitis C virus
683   infection. *Gastroenterology* **144**, 414-425 e417 (2013).

31. Wolk, K.*, et al.* Maturing dendritic cells are an important source of IL-29 and IL-20 that
may cooperatively increase the innate immunity of keratinocytes. *J Leukoc Biol* **83**,
1181-1193 (2008).

32. Yin, Z.*, et al.* Type III IFNs are produced by and stimulate human plasmacytoid dendritic
cells. *J Immunol* **189**, 2735-2745 (2012).

33. Channappanavar, R.*, et al.* Dysregulated Type I Interferon and Inflammatory
Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected
Mice. *Cell Host Microbe* **19**, 181-193 (2016).

34. Davidson, S., Crotta, S., McCabe, T.M. & Wack, A. Pathogenic potential of interferon
alphabeta in acute influenza infection. *Nat Commun* **5**, 3864 (2014).

35. Parker, B.S., Rautela, J. & Hertzog, P.J. Antitumour actions of interferons: implications
for cancer therapy. *Nat Rev Cancer* **16**, 131-144 (2016).

36. Broggi, A., Tan, Y., Granucci, F. & Zanoni, I. IFN-lambda suppresses intestinal
inflammation by non-translational regulation of neutrophil function. *Nat Immunol* **18**,
1084-1093 (2017).

37. Broggi, A.*, et al.* Type III interferons disrupt the lung epithelial barrier upon viral
recognition. *Science* **369**, 706-712 (2020).

38. Hadjadj, J.*, et al.* Impaired type I interferon activity and inflammatory responses in
severe COVID-19 patients. *Science* **369**, 718-724 (2020).

39. Major, J.*, et al.* Type I and III interferons disrupt lung epithelial repair during recovery
from viral infection. *Science* **369**, 712-717 (2020).

40. Tokunaga, R.*, et al.* CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A
target for novel cancer therapy. *Cancer Treat Rev* **63**, 40-47 (2018).

41. Kameda, M.*, et al.* CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary
inflammation associated with autoimmunity in patients with collagen vascular
diseases-associated interstitial lung disease and interstitial pneumonia with
autoimmune features. *PLoS One* **15**, e0241719 (2020).

42. Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S. & Proost, P. Overview of the
Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-
Inducible CXC Chemokine Receptor 3 Ligands. *Front Immunol* **8**, 1970 (2017).

43. Chi, Y.*, et al.* Serum Cytokine and Chemokine Profile in Relation to the Severity of
Coronavirus Disease 2019 in China. *J Infect Dis* **222**, 746-754 (2020).

44. Chang, Y.J., Liu, C.Y., Chiang, B.L., Chao, Y.C. & Chen, C.C. Induction of IL-8 release in
lung cells via activator protein-1 by recombinant baculovirus displaying severe acute
respiratory syndrome-coronavirus spike proteins: identification of two functional
regions. *J Immunol* **173**, 7602-7614 (2004).

45. Barnes, P.J. Chronic obstructive pulmonary disease. *N Engl J Med* **343**, 269-280 (2000).

46. Folkerts, G., Kraneveld, A.D. & Nijkamp, F.P. New endogenous CXC chemokine ligands
as potential targets in lung emphysema. *Trends Pharmacol Sci* **29**, 181-185 (2008).

47. Lichtenthaler, S.F., Lemberg, M.K. & Fluhrer, R. Proteolytic ectodomain shedding of
membrane proteins in mammals-hardware, concepts, and recent developments.
EMBO J **37**(2018).

48. Rose-John, S. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in
Inflammation. *Clin Pharmacol Ther* **102**, 591-598 (2017).

49. Zilber, E.*, et al.* Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV
infection. *AIDS* **33**, 1253-1256 (2019).

50. Hoel, H., *et al.* Soluble T-Cell Immunoglobulin Mucin Domain-3 Is Associated With
Hepatitis C Virus Coinfection and Low-Grade Inflammation During Chronic Human
Immunodeficiency Virus Infection. *Open Forum Infect Dis* **7**, ofaa033 (2020).

51. Mohammadizad, H., Shahbazi, M., Hasanjani Roushan, M.R., Soltanzadeh-Yamchi, M.
& Mohammadnia-Afrouzi, M. TIM-3 as a marker of exhaustion in CD8(+) T cells of
active chronic hepatitis B patients. *Microb Pathog* **128**, 323-328 (2019).

52. Ueland, T., *et al.* Elevated plasma sTIM-3 levels in patients with severe COVID-19. *J*
Allergy Clin Immunol **147**, 92-98 (2021).

53. Hoffmann, M., *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278 (2020).

54. Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease.
Cold Spring Harb Perspect Biol **6**, a016295 (2014).

55. Lagunas-Rangel, F.A. & Chavez-Valencia, V. High IL-6/IFN-gamma ratio could be
associated with severe disease in COVID-19 patients. *J Med Virol* **92**, 1789-1790
(2020).

56. Deshmane, S.L., Kremlev, S., Amini, S. & Sawaya, B.E. Monocyte chemoattractant
protein-1 (MCP-1): an overview. *J Interferon Cytokine Res* **29**, 313-326 (2009).

57. Gschwandtner, M., Derler, R. & Midwood, K.S. More Than Just Attractive: How CCL2
Influences Myeloid Cell Behavior Beyond Chemotaxis. *Front Immunol* **10**, 2759 (2019).

58. Varona, J.F., *et al.* Soluble ICAM 1 and VCAM 1 Blood Levels Alert on Subclinical
Atherosclerosis in Non Smokers with Asymptomatic Metabolic Syndrome. *Arch Med*
Res **50**, 20-28 (2019).

59. Zhang, F., *et al.* IFN-gamma and TNF-alpha drive a CXCL10+ CCL2+ macrophage
phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue
inflammation. *Genome Med* **13**, 64 (2021).

60. Wang, Z., *et al.* COVID-19 Severity Correlates with Weaker T-Cell Immunity,
Hypercytokinemia, and Lung Epithelium Injury. *Am J Respir Crit Care Med* **202**, 606-
610 (2020).

61. Mathew, D., *et al.* Deep immune profiling of COVID-19 patients reveals patient
heterogeneity and distinct immunotypes with implications for therapeutic
interventions. *bioRxiv* (2020).

62. Koutsakos, M., *et al.* Integrated immune dynamics define correlates of COVID-19
severity and antibody responses. *Cell Rep Med* **2**, 100208 (2021).

63. Keskinen, P., Ronni, T., Matikainen, S., Lehtonen, A. & Julkunen, I. Regulation of HLA
class I and II expression by interferons and influenza A virus in human peripheral blood
mononuclear cells. *Immunology* **91**, 421-429 (1997).

64. Gregorova, M., *et al.* Post-acute COVID-19 associated with evidence of bystander T-
cell activation and a recurring antibiotic-resistant bacterial pneumonia. *Elife* **9**(2020).

65. Habel, J.R., *et al.* Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated
with the prominent HLA-A*02:01 phenotype. *Proc Natl Acad Sci U S A* **117**, 24384-
24391 (2020).

66. Tomoda, A., *et al.* Cytokine production and modulation: comparison of patients with
chronic fatigue syndrome and normal controls. *Psychiatry Res* **134**, 101-104 (2005).

67. Montoya, J.G., *et al.* Cytokine signature associated with disease severity in chronic
fatigue syndrome patients. *Proc Natl Acad Sci U S A* **114**, E7150-E7158 (2017).

Table 1

Characteristics	ADAPT participants		HCoV (ADAPT-C)	Unexposed (St Vincent's)	Unexposed (Uni Melbourne)
	'LONG COVID	Matched ADAPT controls			
n	31	31	25	16	30
Mean age (y)	49.6 ± 14.9	48.9 ± 12.8	47.4 ±16.9	37.13 ±10.02	48.13±11.89
Male gender, n (%)	15 (48%)	15 (48 %)	14 (54%)	8 (50%)	15(50%)
Median days after positive SARS-CoV-2 PCR (IQR)	128 (115-142)	120 (115-142)	N/A	N/A	N/A
Ethnicity (n, %-total) - Caucasian	28 (90%)	26 (84%)		12 (75%)	N/A
Severity (n, %-total) - Hospitalised - Community	8 (26%) 23 (74%%)	2/31 (6%) 29/31 (94%)	N/A	N/A	N/A
Co-morbidities (n, %-total) - Yes	12 (39%)	12 (39%)	N/A	N/A	N/A
Transmission - Overseas-acquired	13 (42%)	15/31(48%)	N/A	N/A	N/A
Phenotyping (n)	14	14	N/A	14	-
HCoV positive (n) HKU-1 229E NL63 OC43	-	-	1 14 14 10	-	-
ACE2 assay (n) 3-month 5-month 8-month	26 25 27	29 24 29	26 - - -	-	30 - - -

Table 1- *Patient characteristics.* Age, gender , ethnicity and co-morbidities within the cohorts sampled. HCoV patients who were PCR positive for 229E were also positive for NL63.

Figure 1

A

B

Figure 1- *Elevated levels of pro-inflammatory cytokines that persists after month 8 of convalescence.* A) Higher levels of IFN-β, IFN-λ1, CXCL9 (MIG-1), CXCL10 (IP-10), IL-8 and sTIM-3 at 4 months in long COVIDs and asymptomatic matched controls compared to subjects infected with common cold coronavirus (HCoV) and unexposed healthy donors. B) Reduction of cytokine levels at 8 months in MC. IFN-β and IFN-λ1 level in LC were higher than MC at 8 months. Data shown as medians with interquartile ranges. Two-tailed *p* values <0.05 (*) were considered significant. Wilcoxon t-test was used for paired samples at 8 months.

Figure 2

A

Figure 2- Elevated plasma ACE2 activity in SARS-CoV-2 infected subjects that decreases over time. A) Increased ACE2 activity at 3 months and 4 months post SARS-CoV-2 infection, that decreased at 8 months in both groups. Minimal ACE2 in HCoV and unexposed donors from University of Melbourne (Unexposed). LC (Long COVID), MC (asymptomatic matched controls). Data shown as column graphs showing medians with interquartile ranges. Two-tailed p values <0.05 (*) were considered significant.

Figure 3- *high inter-analyte correlations and the 4 best features in long COVID.* A) Spearman correlation and hierarchical clustering comparing Severity, Gender, Ethnicity and Age with ACE2 and 28 other analytes at 4 months. Diffuse elevation of inflammatory analytes in Long COVIDs (highlighted in red triangle). B) No diffuse inflammatory profile in matched controls at 4 months. *p* values <0.05 were considered significant (*<0.05, **<0.01, ***<0.001). C) Best 4

analytes highly associated with LC eere: IL-6, IFN-γ, MCP-1 (CCL2) and VCAM-1. These four analytes gave an accuracy of 75.9%, and an F1 score of 0.759. TP= true positive, TN= true negative, FP= false positive and FN= false negative D) Visualisation of the domain boundary with two-dimensional projections. Red dots are long COVIDs, Blue dots are matched controls. Axes represent concentrations pg/mL.

Figure 3

C

Best 4 analytes	Accuracy	F1 Score	TP	TN	FP	FN
IL-6, IFN-γ , MCP-1 , VCAM-1	0.759	0.759	22	22	7	7

D

Figure 4

Figure 4

Figure 4- *Distinct activation phenotype in non-lymphoid cells and absence of naïve T and B cells found in long COVID*. A) Dimensional reduction utilising TriMap and clustering with Phenograph was used to visualise immune cell phenotypes. 5 populations consisting of un-activated naïve and cytotoxic phenotypes were absent in LC compared to MC at 3 months. Absent populations are outlined in red (middle panel), with frequency of population shown in bar graph. B) 3 naive populations remained absent in peripheral blood at 8 months in Long COVIDs. C) Activated non-lymphoid (myeloid) cells with combined expression of CD38 and HLA-DR in LC and MC at 3 months but was not reduce at 8 months in LCs. D) More activated monocytes and (E) plasmacytoid dendritic cells (pDCS) in LC compared to MC at 3 and 8 months. F) No difference in PD-1 levels on CD4 T cells, but higher expression by CD8+ T cells in LC at both timepoints. Data shown as medians with interquartile ranges. G) Higher Tim-3 expressed onCD8+ T cells in LC at 3months. Two-tailed *p* values <0.05 (*) were considered significant.

Supplementary Table 1

Participant	Symptom Severity at acute initial infection (Mild=1, Moderate=2, Severe=3)	Gender (0=F, 1=M)	Ethnicity	Long-COVIDs Significant Symptom Criteria (1=Long COVID)	Symptoms at 8 months	Long-COVID at 8 months (1=Long COVID)
1	1	0	Caucasian/White	1		
2	3	1	Caucasian/White	1		
3	3	1	Caucasian/White	1	Yes	1
4	1	0	Caucasian/White	1	Yes	1
5	3	1	Asian	0	No	0
6	1	1	Caucasian/White	1	Yes	1
7	3	1	Caucasian/White	1	Yes	1
8	3	1	Caucasian/White	1	Yes	1
9	2	1	Caucasian/White	0	No	0
10	2	1	Caucasian/White	0	No	0
11	1	1	Caucasian/White	0	No	0
12	3	1	Caucasian/White	1	Yes	1
13	1	0	Caucasian/White	0	No	0
14	2	0	Caucasian/White	1	Yes	1
15	1	1	Caucasian/White	0	No	0
16	2	0	Caucasian/White	0	No	0
17	2	1	Caucasian/White	0	No	0
18	2	0	Hispanic or Latino	1	Yes	1
19	1	1	Caucasian/White	0	No	0
20	2	0	Caucasian/White	0		
21	2	1	Caucasian/White	0	No	0
22	2	0	Caucasian/White	1	Yes	1
23	2	0	Asian	0	No	0
24	2	1	Caucasian/White	0	No	0
25	2	0	Caucasian/White	1	No	0
26	2	1	Caucasian/White	0	No	0
27	2	1	Caucasian/White	1	No	0
28	1	0	Other	0	No	0
29	2	0	Caucasian/White	0	No	0
30	2	0	Caucasian/White	0	No	0
31	2	1	Caucasian/White	1	No	0
32	1	1	Caucasian/White	0	No	0
33	1	0	Caucasian/White	0	No	0
34	1	0	Caucasian/White	0	No	0
35	2	0	Caucasian/White	1	Yes	1
36	2	0	Caucasian/White	0	No	0
37	2	0	Hispanic or Latino	0	No	0
38	1	0	Caucasian/White	0	No	0
39	1	0	Caucasian/White	0	No	0
40	1	1	Caucasian/White	1	No	0
41	3	1	Caucasian/White	0		
42	1	1	Caucasian/White	0	No	0
43	1	0	Caucasian/White	0	No	0
44	2	0	Caucasian/White	1	Yes	1
45	3	0	Caucasian/White	1	Yes	1
46	1	0	Caucasian/White	1	Yes	0
47	2	1	Caucasian/White	1	Yes	1
48	1	1	Caucasian/White	0	No	0
49	2	0	Caucasian/White	1	Yes	1
50	2	0	Caucasian/White	0	No	0
51	1	0	Caucasian/White	1	Yes	1
52	2	0	Caucasian/White	1	Yes	1
53	2	0	Caucasian/White	1	Yes	1
54	3	1	Caucasian/White	1	Yes	1
55	2	1	Caucasian/White	1	Yes	1
56	2	0	Asian	1	Yes	1
57	2	1	Caucasian/White	1	Yes	1
58	1	0	Asian	0	No	0
59	2	0	Caucasian/White	1	Yes	1
60	2	1	Caucasian/White	1	Yes	1
61	3	1	Hispanic or Latino	1	Yes	1
62	1	1	Caucasian/White	0	No	0

Supplementary Table 1- *Clinical data of Long COVID and Matched controls.* A) Symptom severity, Gender, Ethnicity of 31 long COVID and 31 asymptomatic matched controls. Subject 15 was on Everilomus and Mycophenolate due to prior renal transplant, and subject 45 was on Plaquenil for treatment of SLE.

804   # Supplementary Table 2

	Median date of symptom onset	Fever / chills	Cough	Rhinorrhoea / runny nose	Anosmia / loss of smell	Ageusia / loss of taste	Sore throat	Shortness of breath	Chest pain	Nausea / Vomiting	Diarrhoea	Headache	Myalgia / muscle aches	Arthralgia / joint aches	Malaise / weakness	Fatigue	Other
Long COVID (n=31)	19/03/2020	17	19	13	13	12	14	15	21	10	9	10	24	22	14	19	25
Matched Controls (n=31)	18/03/2020	15	15	14	10	9	12	8	4	3	8	18	17	14	16	26	7

Supplementary Table 2- *Symptoms at acute initial infection.* A) Median date of symptom onset for two cohort groups (long COVID and matached control). Numbers represent subjects with reported symptom at acute initial infection.

Supplementary Figure 1

Supplementary Figure 1- *Gating strategy.* A) Representative dot plot and gating strategy for flow cytometry analysis. Cells use for downstream analysis were live singlet expressing lineage markers, mDC (myeloid dendritic cells), pDC (plasmacytoid dendritic cells.

Supplementary Figure 2

A

B

C

Groups	IFN-β	IFN-λ1	IL-8	CXCL9	CXCL10	sTIM-3
LC Median [IQR]	48.72 [24.2-67.77]	15.31 [8.83-37.21]	13.9 [7.78-21.97]	306.33 [167.19-494.19]	44.5 [26.21-79.29]	Log_{10} 3.72 [3.42-3.85])
MC	45.47 [20.04-80.39]	20.29 [8.83-20.29]	11.82 [5.23-18.55]	307.25 [162.25-443.33]	42.47 [18.96-61.25]	Log_{10} 3.69 [3.42-3.77]
HCoV	6.15 [6.15-6.72]	6.26 [6.26-7.59]	12.28 [4.86-18.83]	183.56 [131.82-253.55]	20.69 [12.03-61.25]	Log_{10} 3.55 [3.38-3.63]
Unexposed	6.65 [6.15-8.30]	6.32 [6.26-8.02]	3.45 [3.45-4.19]	180.9 [79.06-277.12]	13.9 [7.78-21.97]	Log_{10} 3.515 [3.35-3.69]

Supplementary Figure 2- *No difference in levels of 22 analytes following SARS-CoV-2 infection.* A) No differences in IL-1b, IL-6, TNF-α, IL-12p70, IFN-α2, IFN-λ2/3, GM-CSF, IL-10, IFN-γ, TGF-β1 or IL-13 levels between the 4 groups at 4 months. B) No differences in sCD25, PTX3, CCL2(MCP-1), IL-33, PD-1, IL-5, IL-9, MPO, PECAM-1, ICAM-1 or VCAM-1 levels between the 4 groups. Data shown as medians with interquartile ranges. C) Median and IQR values for 4 groups at 4 months.

Supplementary Figure 3

Supplementary Figure 3- *Reduction of some cytokines at 8 months.* . A) IFN-β and IFN-λ1 levels remained higher in LC at 8 months compared to HCoV and unexposed. B) Significant reduction of TGF-β1 at 8 months in LC. C) Decrease in most analytes at 8 months. Data shown as medians with interquartile ranges.

A

B

Supplementary Figure 4- *Correlation matrices from HCoV and unexposed donors.* Spearman correlation comparing indicated features in LC (A) and MC (B) at 8months and common cold coronavirus infected donors-HCoV (C) and unexposed healthy donors (D).

C

D

Supplementary Figure 5

Supplementary Figure 5- *Clustering of cell phenotypes. A*) Example of cell cluster phenotype identification using CellExplorer plugin on Flowjo. Cluster 14 is equivalent to population 3, identified as CCR7+CD45RA+CD27+ naïve CD4+ T cells. TriMap of T cell, B cell, NK Cell and myeloid cell clusters (outlined in red) at 3 months (B) and 8 months (C).

Supplementary Figure 5

Supplementary Figure 6

A

All Combined	Unexposed	LC	MC

B

Population	Phenotype	All	Unexposed	LC	MC
1	CD4+CD127highTIM-3midCD57+CD38lowHLA-DRmid	2770	609	1937	224
2	CD4+CD127midTIM-3midCD38midHLA-DRlow	1973	314	1625	34
3	CD4+CD127lowTIM-3lowCD38lowHLA-DRmid	1843	208	408	1227
4	CD4+CD127midTIM-3highCD38midHLA-DRlow	1379	101	923	355
5	CD4+CD127low TIM-3negCD38lowHLA-DRlow	818	194	0	624
6	CD8+CD127highGzmB+CD57+CD38midHLA-DRmid	920	260	549	111
7	CD8+CD127midGzmB+CD57-CD38lowHLA-DRlow	876	97	629	150
8	CD8+CD127lowGzmB-CD57-CD38lowHLA-DRlow	323	101	0	222
9	CD8+CD127lowGzmB-CD57-CD38midHLA-DRlow	361	32	89	240

C

All Combined	Unexposed	LC	MC

D

Population	Phenotype	All	Unexposed	LC	MC
1	CD127highTIM-3midCD38midHLA-DRlow	725	142	362	221
2	CD127midTIM-3lowCD38midHLA-DRmid	686	105	371	210
3	CD127midTIM-3lowCD38lowHLA-DRlow	676	516	59	101
4	CD127lowTIM-3negCD38lowHLA-DRmid	567	358	0	209
5	CD127midTIM-3lowCD38lowHLA-DRmid	153	67	53	33

Supplementary Figure 6

E — Naïve T cells

F — Naïve B cells

Supplementary Figure 6- *Deciphering naïve phenotypes.* Representative TriMap and phenograph clustering of CCR7+CD45RA+ naïve T cells (A) and IgD+CD27- naïve B cells (C). Red gates and text represent un-activated naïve subsets absent in long COVID subjects. Phenotype and cell frequencies from naïve T cell s (B) and naïve B cells (D). CD127 expression on differing naïve T cell (E) and naïve B cell (F) populations (all data combined). Red text highlights subsets absent in long COVID. Unexposed, LC (long COVID0, and MC (asymptomatic matched controls).

Supplementary Figure 7

Supplementary Figure 7- *Activated phenotypes.* (A) No difference in activated state of Myeloid dendritic cells (mDCs) at 3 months and 8 months. (B) No difference between LC and MC at 3 and 8 months when co-expression of PD-1 and Tim-3 were examined (long COVID, and MC (asymptomatic matched controls).

825